Pregnancy marks a profoundly special journey for expectant parents, filled with dreams of their baby's health and happiness. Introducing the "Non-Invasive Fetal Trisomy Y Test" or NIFTY testing service from Medical Line Lab, a revolutionary option for parents seeking to screen their baby's chromosomal health and ensure a safe entry into the world.

Unveiling NIFTY: A Glimpse into Fetal Chromosomal Abnormality Screening

NIFTY, or Non-Invasive Fetal Trisomy Y Test, stands as a remarkable screening solution for detecting chromosomal abnormalities within the fetus, offering unparalleled accuracy and specificity. Developed using cutting-edge assay technology by BGI, a global leader in clinical genetic services, NIFTY empowers parents with crucial insights into their baby's genetic health.

NIFTY testing involves the collection of the mother's blood, from which genetic information is extracted from substances secreted by the placenta. These substances circulate in the mother's bloodstream during pregnancy, collectively known as Cell-Free Fetal DNA (cffDNA). This test is optimally performed between the 10th and 24th weeks of gestation.

Subsequent to sample collection, obtained data is meticulously analyzed to assess the risk of chromosomal abnormalities across the 23 pairs of chromosomes. Notably, this includes the commonly screened chromosomes 21, 18, and 13, which correspond to Down syndrome, Edwards syndrome, and Patau syndrome, respectively. Additionally, NIFTY detects abnormalities in the number of sex chromosomes and identifies instances of deletion or duplication across up to 84 chromosomes.

Unlocking NIFTY's Insight: A Comprehensive Understanding of Genetic Abnormalities

NIFTY’s preliminary screening primarily targets common chromosomal abnormalities, including syndromes associated with an extra chromosome, such as Down syndrome (extra 21st chromosome), Edwards syndrome (extra 18th chromosome), and Patau syndrome (extra 13th chromosome). Furthermore, NIFTY delves into the realm of sex chromosomes, determining not just the gender of the fetus but also revealing any anomalies caused by the presence of an incorrect number of sex chromosomes. This holistic approach facilitates a well-rounded and effective care strategy.

Pioneering Techniques in Chromosomal Health Assessment

At the core of NIFTY's effectiveness lies cffDNA, fragments of fetal DNA present in the maternal bloodstream. The NIFTY test requires a mere 8-10 ml of maternal blood, from which cffDNA is extracted. The extracted data is then compared against an extensive database to provide comprehensive analysis and risk assessment for chromosomal abnormalities.

Leveraging the state-of-the-art Massive Parallel Sequencing (MPS) method, NIFTY reads DNA sequences from the maternal blood. This technology, paired with Next-Generation Sequencing (NGS), analyzes millions of data points from a single blood sample, producing highly accurate and reliable results. Advanced bioinformatics programs further enhance the precision of the analysis, ensuring that NIFTY's outcomes are both trustworthy and insightful.

Trust NIFTY for a Bright Future

Embark on your journey towards parenthood with the confidence that comes from informed decisions. NIFTY screening service from Medical Line Lab equips you with the knowledge to navigate your baby's genetic health journey, making your experience as joyous and safe as possible.

Address 1: 2782, 128/4 Lat Phrao Road,

Address 2: Khlong Chan, Bang Kapi District,

Province: Bangkok